Full Text View
Tabular View
Study Results
Related Studies
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
This study has been completed.
First Received: September 12, 2005   Last Updated: June 3, 2009   History of Changes
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00190749
  Purpose

This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.


Condition Intervention Phase
Schizophrenia
Schizoaffective Disorder
 Drug: olanzapine
Drug: risperidone
 Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety Study
Official Title: Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
Drug Information available for: Risperidone Olanzapine
U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Change in Baseline to Last Observation In Normalized Insulin Sensitivity Index at Low Insulin Phase Using Change in Weight as a Covariate [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Weight. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Body Mass Index (BMI) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Ratio of Visceral Fat Area to the Subcutaneous Fat Area. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Brief Psychiatric Rating Scale Scores. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Clinical Global Impression - Severity of Illness Scale Scores. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Abnormal Involuntary Movement Scale Scores. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlation Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Barnes Akathisia Scale Scores. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in the Simpson Angus Scale Scores. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Waist Circumference. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Visceral Fat Area. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Subcutaneous Fat Area. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pairwise Correlations Between Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Eating Behavior Assessment Scale Scores. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Within-and Between-Treatment Group Changes From Baseline to Endpoint in Body Mass Index. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Weight. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Waist Circumference. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Visceral Fat Area. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Subcutaneous Fat Area. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in the Ratio of the Visceral Fat Area to the Subcutaneous Fat Area. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Scores. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Clinical Global Impression - Severity of Illness Scores. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Abnormal Involuntary Movement Scale Scores. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Barnes Akathisia Rating Scale (BARS) Scores [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Simpson Angus Scale Scores. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes From Baseline to Endpoint in Eating Behavior Assessment Scale Scores. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes in Fasting Lipid Parameters Including Total Cholesterol. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes in Fasting Lipid Parameters Including Direct Low Density Lipoprotein (LDL). [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes in Fasting Lipid Parameters Including High Density Lipoprotein (HDL). [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes in Fasting Lipid Parameters Including Triglycerides. [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of Both the Within-Treatment Group and Between-Treatment Group Changes in Fasting Lipid Parameters Including Lipoprotein Subclasses. [ Time Frame: baseline and 12 weeks. ] [ Designated as safety issue: Yes ]

Enrollment: 130
Study Start Date: October 2003
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Experimental Drug: olanzapine
5-20mg, oral, capsules, daily, 12 weeks.
B: Active Comparator Drug: risperidone
2-6mg, oral, capsules, twice daily (BID), 12 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-65 years old
  • Diagnosed with Schizophrenia or Schizoaffective disorder
  • Ability to visit the Dr's office for scheduled visits

Exclusion Criteria:

  • Women who are pregnant or breastfeeding
  • Have a BMI greater than 40
  • Have diabetes, heart disease or any other unstable illness
  • Have known positive HIV
  • Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable antipsychotics
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00190749

Locations
United States, California
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Diego, California, United States, 92161
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
Lilly Clinical Trial Registry  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Eli Lilly ( Chief Medical Officer )
Study ID Numbers: 5296, F1D-MC-S014
Study First Received: September 12, 2005
Results First Received: June 3, 2009
Last Updated: June 3, 2009
ClinicalTrials.gov Identifier: NCT00190749     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Olanzapine
Psychotropic Drugs
Antiemetics
Schizophrenia
Serotonin Antagonists
Pathologic Processes
Mental Disorders
Therapeutic Uses
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features
 Disease
Tranquilizing Agents
Gastrointestinal Agents
Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Agents
Autonomic Agents
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services